Sysmex Q1 Beats Expectations, Strong Americas Demand Boosts Confidence

Overview

This is a commentary report from JPMorgan following Sysmex's release of its Q1 results for fiscal year 2026. The core conclusion is that Q1 results significantly beat expectations, confirming strong demand in the Americas and leaving a good impression on the market. However, the impact of China's clinical testing fee standardization policy remains unclear; the report anticipates signals indicating the 'end of bad news.' The report maintains an Overweight rating and a 1600 JPY target price, expecting a moderately positive stock price reaction.

Core views

Reasons for Earnings Beat and Americas Recovery: Q1 operating profit reached 14.8 billion JPY, approximately 1.5 times the Bloomberg consensus estimate of 9.6 billion JPY, and exceeded company guidance by approx. 2 billion JPY. The report attributes the beat primarily to the Americas—post-pandemic, the delivery cycle from equipment orders to revenue recognition had been extended, leading to increased backlog in FY2025. Recently, this cycle has normalized, driving a significant increase in revenue recognition in the Americas during Q1. On the sales side, the Americas hematology business was particularly strong, while EMEA and APAC also performed steadily, aided by a weak yen. Concerns Regarding China and Product Mix: While overall sales in China were above guidance, internal structure showed divergence—the coagulation business was below guidance, while hematology was strong. Gross margins were affected by a worsening product mix, primarily due to an increased share of hematology equipment sales in the Americas; SG&A, excluding exchange rate effects, basically met guidance. Management has raised operating profit guidance for H1 FY2026 and the full year by 2 billion JPY and plans to announce a business portfolio review with Q2 results. The report expects the market to form expectations regarding improvements in low-margin businesses. Profit Growth Drivers and Short-term Volatility Factors: The report believes that profit growth in the coagulation business and Americas/Europe hematology business (driven by the expansion of the XR series blood analyzers) will drive the stock price; short-term stock prices will fluctuate around China business performance and the growth rate of coagulation sales in the US, Europe, and China. Valuation and Target Price Logic: The December 2026 target price of 1600 JPY is based on estimated FY2026 EPS and a 23x P/E ratio. This target P/E is higher than the average of 18x for the Japanese MedTech sector, but the report considers the premium justified by Sysmex's high market share and high overseas sales growth. Historically, since the launch of the XN series in 2013, the stock's average P/E has been 34x (excluding the severely disrupted pandemic years of 2020-22). The current price of 1652 JPY is slightly above the target price.

Analysis framework

The report adopts a classic problem-focused approach: first, clearly breaking down the reasons for the Q1 beat, and then determining whether this change is sustainable or a short-term fluctuation. Analysis of the Americas is particularly key—the report does not stop at the surface-level statement of 'strong Americas sales' but traces back to the normalization of the order-to-revenue recognition cycle, explaining the mechanism behind the release of past backlog orders, which helps investors assess the sustainability of Americas demand. Simultaneously, the report links the decline in gross margins to changes in product mix, pointing out that this is a result of the increased share of hematology equipment sales in the Americas, representing a short-term cost of growth structure rather than deteriorating demand. For China, the report uses a framework of 'when will the bad news end': although the timing and magnitude of policy impacts are uncertain, once the impact of clinical testing fee standardization becomes clear, market expectations can be partially digested, increasing the probability of upside in stock prices. At the valuation level, the report uses a dual-dimensional comparison of sector averages and historical average P/E ratios to argue for the rationality of the 23x target P/E.

Methodology notes

• Company Fundamentals and Financial FrameworkProfit Quality Analysis

  Decompose revenue beats into volume/region/currency contributions; attribute gross margin changes to product mix shifts

  The report distinguishes sales performance across regions (Americas, EMEA, APAC, China) and attributes the decline in gross margins to a worsening product mix caused by an increased share of hematology equipment sales in the Americas, helping readers understand the source and quality of profit growth.

• Industry/Industrial Analysis FrameworkVolume-price decomposition

  Impact of changes in the equipment order-to-revenue recognition cycle (lead time) on revenue pacing

  Extended delivery cycles since the pandemic led to order backlogs; recent normalization of these cycles has driven concentrated revenue recognition. This is an extension of common volume-price decomposition in the medical device industry—breaking down revenue changes into two dimensions: order flow and recognition timing.

• Valuation methodsPE/PEG valuation

  Target price based on FY2026 EPS estimates and 23x P/E

  The report derives the target price by multiplying the FY2026 EPS estimate by a 23x target P/E, using sector average (18x) and historical average (34x) as reference points to justify the multiple.

• Event Gambling and Behavioral FinanceExpectation Gap/Expectation Management

  'Waiting for the end of bad news from China' and expectation adjustments brought by the business portfolio review

  The report argues that once the impact of China's clinical testing fee standardization becomes clear, the 'bad news' can be partially digested by the market; simultaneously, the announcement of the business portfolio review is likely to enhance market expectations for improvements in low-margin businesses. This represents typical logic of expectation gap management.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sysmex (6869.T)

  The subject directly covered by the report with an Overweight rating; strong Americas hematology business and normalization of the order recognition cycle drove the earnings beat

  Strengths

  High market share; high overseas sales growth; expansion of the XR series blood analyzers driving profit growth in Americas/Europe hematology business; coagulation business expected to contribute to profit growth

  Weaknesses

  China coagulation business below guidance; gross margins affected by worsening product mix; uncertainty brought by China's clinical testing fee standardization policy

  Comparison

  Target P/E of 23x is higher than the Japanese MedTech sector average of 18x, but the report considers the premium reasonable given the high market share and high overseas growth rate

  Risks

  XR series sales underperformance in the US; coagulation sales underperformance in the US, Europe, and China; slowdown in China business due to economic slowdown, government policy, or deteriorating competitive environment

Key data

• Q1 Operating Profit14.8 Billion JPYApproximately 1.5 times the market consensus estimate of 9.6 billion JPY, exceeding guidance by approx. 2 billion JPY
• Earnings Guidance Increase2 Billion JPYManagement raised operating profit guidance for H1 FY2026 and the full year
• Target Price1600 JPYDecember 2026 target price, based on 23x FY2026 P/E
• Current Stock Price1652 JPYClosing price on August 7, 2026, already slightly above the target price
• Target P/E Ratio23xHigher than the Japanese MedTech sector average of 18x, lower than the historical average of 34x
• Historical Average P/E34xSince the launch of the XN series in 2013, excluding pandemic disruption years 2020-22

Impact & implications

The report believes that strong demand in the Americas and the normalization of the order recognition cycle have significantly improved the dispersion of Q1 results, helping to strengthen market confidence in the sustainability of Sysmex's overseas business. The decline in gross margins is interpreted as a short-term result of the increased proportion of high-growth products, rather than structural deterioration. The announcement of the business portfolio review may become a positive catalyst for the stock price, as the market is likely to form expectations for improvements in low-margin businesses. Regarding China, once the scope of the impact from clinical testing fee standardization is clarified, the report believes the probability of the 'end of bad news' increases, offering greater upside potential for the stock. Overall, this is a commentary with an optimistic tone, believing that the company's fundamentals are stabilizing, but short-term developments still need to be observed regarding Chinese policies and the realization of coagulation sales in the US and Europe.

Risks

• XR series blood analyzer sales underperforming expectations in the US
• Coagulation business sales underperforming expectations in the US, Europe, and China
• Slowdown in China business due to economic slowdown, government policy, or deteriorating competitive environment
• Uncertainty regarding the actual timing and magnitude of the impact of China's clinical testing fee standardization policy

What to watch

• Content of the business portfolio review announced with Q2 results and improvement measures for low-margin businesses
• Actual realization of the impact of China's clinical testing fee standardization policy starting from Q4 FY2026
• Sales growth rate of coagulation business in the US and Europe and progress of XR series sales in the US
• Structural performance of hematology and coagulation businesses in China